Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A5414 SPECTRA-TB
PACTR202610507009584Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of isoniazid, rifampicin, ethambutol, pyrazinamide, rifapentine and 1 more in pulmonary tuberculosis (TB) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Sustained cure at 52 weeks after randomization and Occurrence of at least one new Grades 3-5 adverse event during the 28 weeks following randomization. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
isoniazidrifampicinethambutolpyrazinamiderifapentine
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202610507009584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202610507009584.